{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:48:42Z","timestamp":1781765322028,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To systematically review the literature surrounding medication-associated thyroid eye disease (TED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted from inception to the 31st of March 2025 on PubMed, EMBASE and Web of Science. Studies describing medication-associated thyroid dysfunction and the subsequent development of TED were included. Articles without thyroid dysfunction and\/or the absence of orbitopathy were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 23 studies met the inclusion criteria. Implicated medications included alemtuzumab, immune checkpoint inhibitors (ICI), amiodarone and lenalidomide. The mean onset of thyroid dysfunction from commencement of alemtuzumab was 26.3\u2009\u00b1\u200912.2 months (Range: 7 to 53.3 months); and the mean onset of developing orbitopathy from thyroid dysfunction was 19.9\u2009\u00b1\u200921.4 months (Range: 0 to 96 months). Graves\u2019 disease was the most common condition resulting in the development of alemtuzumab-associated TED. ICIs reported to cause TED included ipilimumab (anti-CTLA-4 drug), tremelimumab (anti-CTLA-4 drug), durvalumab (PD-1 inhibitor) and nivolumab (PD-1 inhibitor). Anti-CTLA4 drugs, such as ipilimumab and tremelimumab, were the most common agents implicated in the development of ICI-associated TED. ICIs may also incite orbital inflammation in the absence of thyroid dysfunction. A single case-report of amiodarone- and lenalidomide-associated TED was noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Medication-associated TED is an important differential consideration in the work-up of orbital inflammatory disease. The clinico-radiological manifestations and the principles of management of medication-associated TED were similar to that of\n                      <jats:italic>de novo<\/jats:italic>\n                      TED. Certain medications, such as various ICIs, may demonstrate different clinical phenotypes of orbital inflammation, inciting either TED or a \u201cTED-like\u201d orbitopathy without evidence of underlying thyroid dysfunction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-07089-w","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:47:17Z","timestamp":1768636037000},"page":"1129-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medication-associated thyroid eye disease: a review"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-1793","authenticated-orcid":false,"given":"Terence","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Selva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"7089_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03352-x","volume":"44","author":"K Rana","year":"2024","unstructured":"Rana K, Caltabiano C, Beecher M, Patel S, Slattery J, Chan WO, Davis G, Selva D (2024) Lacrimal gland enlargement in thyroid eye disease. Int Ophthalmol 44:431. https:\/\/doi.org\/10.1007\/s10792-024-03352-x","journal-title":"Int Ophthalmol"},{"key":"7089_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03141-6","volume":"44","author":"K Rana","year":"2024","unstructured":"Rana K, Garg D, Yong LSS, Leyden J, Patel S, Slattery J, Davis G, Chan WO, Selva D (2024) Asymmetric proptosis in thyroid eye disease. Int Ophthalmol 44:206. https:\/\/doi.org\/10.1007\/s10792-024-03141-6","journal-title":"Int Ophthalmol"},{"key":"7089_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020312","author":"KR Hutchings","year":"2023","unstructured":"Hutchings KR, Fritzhand SJ, Esmaeli B, Koka K, Zhao J, Ahmed S, Debnam JM (2023) Graves\u2019 eye disease: clinical and radiological diagnosis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020312","journal-title":"Biomedicines"},{"key":"7089_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","volume":"43","author":"L Scappaticcio","year":"2020","unstructured":"Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannav\u00f2 S, Campenn\u00ec A, Ruggeri RM, Giovanella L, Trimboli P (2020) Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest 43:219\u2013229. https:\/\/doi.org\/10.1007\/s40618-019-01105-7","journal-title":"J Endocrinol Invest"},{"key":"7089_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","volume":"77","author":"M Cossburn","year":"2011","unstructured":"Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573\u2013579. https:\/\/doi.org\/10.1212\/WNL.0b013e318228bec5","journal-title":"Neurology"},{"key":"7089_CR6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa453","author":"A Sovetkina","year":"2020","unstructured":"Sovetkina A, Nadir R, Scalfari A, Tona F, Murphy K, Rigoni E, Dorsey R, Malik O, Nandoskar A, Singh-Curry V, Nicholas R, Martin N (2020) Development of autoimmune thyroid disease in multiple sclerosis patients post-alemtuzumab improves treatment response. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa453","journal-title":"J Clin Endocrinol Metab"},{"key":"7089_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","volume":"33","author":"JCP Roos","year":"2019","unstructured":"Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R (2019) Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves\u2019 orbitopathy: a case series. Eye Lond 33:223\u2013229. https:\/\/doi.org\/10.1038\/s41433-018-0282-1","journal-title":"Eye Lond"},{"key":"7089_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80\u201389. https:\/\/doi.org\/10.1210\/jc.2013-2201","journal-title":"J Clin Endocrinol Metab"},{"key":"7089_CR9","doi-asserted-by":"publisher","first-page":"821EP","DOI":"10.4158\/EP13020.RA","volume":"19","author":"AA Aranha","year":"2013","unstructured":"Aranha AA, Amer S, Reda ES, Broadley SA, Davoren PM (2013) Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a liew. Endocr Pract 19:821EP \u2013 828. https:\/\/doi.org\/10.4158\/EP13020.RA","journal-title":"Endocr Pract"},{"key":"7089_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ccr3.1486","volume":"6","author":"LN Cima","year":"2018","unstructured":"Cima LN, Lambrescu IM, Stejereanu L, Colita A, Or R, Fica S (2018) Graves\u2019 orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy? Clin Case Rep 6:867\u2013870. https:\/\/doi.org\/10.1002\/ccr3.1486","journal-title":"Clin Case Rep"},{"key":"7089_CR11","doi-asserted-by":"publisher","first-page":"A846","DOI":"10.1210\/jendso\/bvab048.1727","volume":"5","author":"P Kazakou","year":"2021","unstructured":"Kazakou P, Tzanetakos D, Vakrakou AG, Tzartos JS, Anagnostouli M, Koutsis G, Andreadou E, Evangelopoulos ME, Kilidireas C, Zapanti E (2021) Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients. J Endocr Soc 5:A846. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1727","journal-title":"J Endocr Soc"},{"key":"7089_CR12","doi-asserted-by":"publisher","DOI":"10.1530\/etj-23-0236","author":"I Muller","year":"2024","unstructured":"Muller I, Maioli S, Armenti M, Porcaro L, Curr\u00f2 N, Iofrida E, Pignataro L, Manso J, Mian C, Geginat J, Salvi M (2024) Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab. Eur Thyroid J. https:\/\/doi.org\/10.1530\/etj-23-0236","journal-title":"Eur Thyroid J"},{"key":"7089_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00415-023-11995-6","volume":"271","author":"P de Rodr\u00edguez Vera G\u00f3mez","year":"2024","unstructured":"de Rodr\u00edguez Vera G\u00f3mez P, M\u00e9ndez Muros M, Torres Cuadro A, de Toyos S\u00e1enz Miera FJ, L\u00f3pez Ruiz R, Guerrero V\u00e1zquez R, Garc\u00eda Gonz\u00e1lez JJ, Garrido Hermosilla AM, Mart\u00edn Hern\u00e1ndez T (2024) Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis. J Neurol 271:486\u2013496. https:\/\/doi.org\/10.1007\/s00415-023-11995-6","journal-title":"J Neurol"},{"key":"7089_CR14","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/iop.0000000000000310","volume":"32","author":"T Trinh","year":"2016","unstructured":"Trinh T, Haridas AS, Sullivan TJ (2016) Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthalmic Plast Reconstr Surg 32:e128\u2013e129. https:\/\/doi.org\/10.1097\/iop.0000000000000310","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR15","doi-asserted-by":"crossref","unstructured":"Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC (2015) Graves\u2019 disease after treatment with Alemtuzumab for multiple sclerosis. Hormones 14: 148EP-153","DOI":"10.14310\/horm.2002.1501"},{"key":"7089_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1210\/clinem\/dgad540","volume":"109","author":"G Ueland","year":"2024","unstructured":"Ueland G, Ueland HO, Stokland AM, Bhan A, Sch\u00f8nberg A, Sollid ST, Morgas DE, Holm\u00f8y T, Lima K, Methlie P, L\u00f8v\u00e5s K, Torkildsen \u00d8, Husebye ES (2024) Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced Graves disease. J Clin Endocrinol Metab 109:344\u2013350. https:\/\/doi.org\/10.1210\/clinem\/dgad540","journal-title":"J Clin Endocrinol Metab"},{"key":"7089_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.14616","volume":"97","author":"J Manso","year":"2022","unstructured":"Manso J, Zhu YH, Margoni M, Rinaldi F, Censi S, Carducci S, Cosma C, Plebani M, Gallo P, Mian C (2022) Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: a real-life and monocentric experience at a tertiary-level centre. Clin Endocrinol (Oxf) 97:331\u2013338. https:\/\/doi.org\/10.1111\/cen.14616","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7089_CR18","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1210\/jc.2018-00359","volume":"103","author":"N Pariani","year":"2018","unstructured":"Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, Lyons G, Jones J, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C (2018) Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab 103:3010\u20133018. https:\/\/doi.org\/10.1210\/jc.2018-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"7089_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.survophthal.2024.03.003","volume":"69","author":"T Ang","year":"2024","unstructured":"Ang T, Chaggar V, Tong JY, Selva D (2024) Medication-associated orbital inflammation: a systematic review. Surv Ophthalmol 69:622\u2013631. https:\/\/doi.org\/10.1016\/j.survophthal.2024.03.003","journal-title":"Surv Ophthalmol"},{"key":"7089_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/iop.0000000000002367","volume":"39","author":"A Nirmalan","year":"2023","unstructured":"Nirmalan A, Blecher N, Hyder S, Couch SM, Godfrey KJ, Stan MN, Bradley EA, Wagner LH, Tooley AA (2023) Alemtuzumab-induced thyroid eye disease: a comprehensive case series and review of the literature. Ophthalmic Plast Reconstr Surg 39:470\u2013474. https:\/\/doi.org\/10.1097\/iop.0000000000002367","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/09273948.2014.1001858","volume":"24","author":"E Papavasileiou","year":"2016","unstructured":"Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM (2016) Ipilimumab-induced ocular and orbital inflammation\u2013a case series and review of the literature. Ocul Immunol Inflamm 24:140\u2013146. https:\/\/doi.org\/10.3109\/09273948.2014.1001858","journal-title":"Ocul Immunol Inflamm"},{"key":"7089_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/01658107.2017.1368090","volume":"42","author":"B Hassanzadeh","year":"2018","unstructured":"Hassanzadeh B, DeSanto J, Kattah JC (2018) Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management. Neuroophthalmology 42:176\u2013181. https:\/\/doi.org\/10.1080\/01658107.2017.1368090","journal-title":"Neuroophthalmology"},{"key":"7089_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","volume":"202","author":"K Bitton","year":"2019","unstructured":"Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, R\u00e9mond AL, Couret C, Champiat S, Labetoulle M, Rousseau A (2019) Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy. Am J Ophthalmol 202:109\u2013117. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.012","journal-title":"Am J Ophthalmol"},{"key":"7089_CR24","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/iop.0000000000000509","volume":"33","author":"CA Sheldon","year":"2017","unstructured":"Sheldon CA, Kharlip J, Tamhankar MA (2017) Inflammatory orbitopathy associated with ipilimumab. Ophthalmic Plast Reconstr Surg 33:S155-s158. https:\/\/doi.org\/10.1097\/iop.0000000000000509","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10637-018-0659-9","volume":"37","author":"C Nardin","year":"2019","unstructured":"Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F (2019) Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. Invest New Drugs 37:375\u2013377. https:\/\/doi.org\/10.1007\/s10637-018-0659-9","journal-title":"Invest New Drugs"},{"key":"7089_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/cji.0000000000000178","volume":"40","author":"A Pushkarevskaya","year":"2017","unstructured":"Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC (2017) Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother 40:282\u2013285. https:\/\/doi.org\/10.1097\/cji.0000000000000178","journal-title":"J Immunother"},{"key":"7089_CR27","doi-asserted-by":"publisher","unstructured":"Jebaraj AP, Etheridge TJ, Winegar BA, Marx DP (2022) Ipilimumab-related orbitopathy: a case report. Orbit (1):5. https:\/\/doi.org\/10.1080\/01676830.2022.2074049","DOI":"10.1080\/01676830.2022.2074049"},{"key":"7089_CR28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/iop.0000000000000081","volume":"31","author":"AD Henderson","year":"2015","unstructured":"Henderson AD, Thomas DA (2015) A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthalmic Plast Reconstr Surg 31:e68-70. https:\/\/doi.org\/10.1097\/iop.0000000000000081","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR29","doi-asserted-by":"publisher","DOI":"10.25107\/2474-1663.1149","volume":"1","author":"D Patel","year":"2016","unstructured":"Patel D, Tremont A, Fuloria J (2016) Orbital myositis secondary to cytotoxic T-lymphocyte-associated protein 4 antibody \u2013 a case report. Clin Oncol 1:1149. https:\/\/doi.org\/10.25107\/2474-1663.1149","journal-title":"Clin Oncol"},{"key":"7089_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.ccm.0000908780.53161.d7","volume":"51","author":"A Thota","year":"2023","unstructured":"Thota A, Kumar S, Pastores S (2023) 762: PEMBROLIZUMAB-INDUCED MYOCARDITIS WITH CONCOMITANT MYOSITIS AND HEPATITIS. Crit Care Med 51:371. https:\/\/doi.org\/10.1097\/01.ccm.0000908780.53161.d7","journal-title":"Crit Care Med"},{"key":"7089_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000485742","volume":"7","author":"P Campredon","year":"2018","unstructured":"Campredon P, Imbert P, Mouly C, Grunenwald S, Mazi\u00e8res J, Caron P (2018) Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Eur Thyroid J 7:84\u201387. https:\/\/doi.org\/10.1159\/000485742","journal-title":"Eur Thyroid J"},{"key":"7089_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28330","volume":"14","author":"D Garcez","year":"2022","unstructured":"Garcez D, Clara AI, Moraes-Fontes MF, Marques JB (2022) A challenging case of eyelid ptosis and diplopia induced by pembrolizumab. Cureus 14:e28330. https:\/\/doi.org\/10.7759\/cureus.28330","journal-title":"Cureus"},{"key":"7089_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.nmd.2020.02.013","volume":"30","author":"M Garibaldi","year":"2020","unstructured":"Garibaldi M, Calabr\u00f2 F, Merlonghi G, Pugliese S, Ceccanti M, Cristiano L, Tartaglione T, Petrucci A (2020) Immune checkpoint inhibitors (ICIs)-related ocular myositis. Neuromuscul Disord 30:420\u2013423. https:\/\/doi.org\/10.1016\/j.nmd.2020.02.013","journal-title":"Neuromuscul Disord"},{"key":"7089_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1416-1","volume":"19","author":"H Kamo","year":"2019","unstructured":"Kamo H, Hatano T, Kanai K, Aoki N, Kamiyama D, Yokoyama K, Takanashi M, Yamashita Y, Shimo Y, Hattori N (2019) Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol 19:184. https:\/\/doi.org\/10.1186\/s12883-019-1416-1","journal-title":"BMC Neurol"},{"key":"7089_CR35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15117","volume":"13","author":"R Abdelmasih","year":"2021","unstructured":"Abdelmasih R, Abdelmaseih R, Reed J (2021) A rare case of statin-induced diplopia: an often-overlooked but reported side effect. Cureus 13:e15117. https:\/\/doi.org\/10.7759\/cureus.15117","journal-title":"Cureus"},{"key":"7089_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02722-8","volume":"15","author":"CY Tian","year":"2021","unstructured":"Tian CY, Ou YH, Chang SL, Lin CM (2021) Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep 15:244. https:\/\/doi.org\/10.1186\/s13256-021-02722-8","journal-title":"J Med Case Rep"},{"key":"7089_CR37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/jop.18.00442","volume":"14","author":"L Rhea","year":"2018","unstructured":"Rhea L, Yoon JW, Jang S (2018) Rapid development of Graves\u2019 ophthalmopathy after treatment with Ipilimumab and recurrence with Pembrolizumab in a patient with previously treated Graves\u2019 disease. J Oncol Pract 14:747\u2013749. https:\/\/doi.org\/10.1200\/jop.18.00442","journal-title":"J Oncol Pract"},{"key":"7089_CR38","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 27:e87-88. https:\/\/doi.org\/10.1097\/IOP.0b013e3181ef72a1","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR39","doi-asserted-by":"publisher","first-page":"W992EP","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992EP \u2013 W1000. https:\/\/doi.org\/10.2214\/AJR.10.6198","journal-title":"AJR Am J Roentgenol"},{"key":"7089_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/eje-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303\u2013307. https:\/\/doi.org\/10.1530\/eje-10-0833","journal-title":"Eur J Endocrinol"},{"key":"7089_CR41","doi-asserted-by":"publisher","first-page":"e51EP","DOI":"10.1016\/j.jtho.2016.12.027","volume":"12","author":"B Ricciuti","year":"2017","unstructured":"Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, Paglialunga L (2017) Long-lasting response to Nivolumab and immune-related adverse events in a nonsquamous metastatic non-small cell lung cancer patient. J Thorac Oncol 12:e51EP \u2013 e55. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.027","journal-title":"J Thorac Oncol"},{"key":"7089_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40618-018-0906-0","volume":"41","author":"E Sabini","year":"2018","unstructured":"Sabini E, Sframeli A, Marin\u00f2 M (2018) A case of drug-induced Graves\u2019 orbitopathy after combination therapy with Tremelimumab and Durvalumab. J Endocrinol Invest 41:877\u2013878. https:\/\/doi.org\/10.1007\/s40618-018-0906-0","journal-title":"J Endocrinol Invest"},{"key":"7089_CR43","doi-asserted-by":"publisher","first-page":"50EP","DOI":"10.1097\/IOP.0000000000001161","volume":"35","author":"O Sagiv","year":"2019","unstructured":"Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B (2019) Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg 35:50EP \u2013 52. https:\/\/doi.org\/10.1097\/IOP.0000000000001161","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/wno.0000000000001148","volume":"41","author":"MM Sun","year":"2021","unstructured":"Sun MM, Seleme N, Chen JJ, Zekeridou A, Sechi E, Walsh RD, Beebe JD, Sabbagh O, Mejico LJ, Gratton S, Skidd PM, Bellows DA, Falardeau J, Fraser CL, Cappelen-Smith C, Haines SR, Hassanzadeh B, Seay MD, Subramanian PS, Williams Z, Gordon LK (2021) Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade. J Neuroophthalmol 41:519\u2013530. https:\/\/doi.org\/10.1097\/wno.0000000000001148","journal-title":"J Neuroophthalmol"},{"key":"7089_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/01676830.2014.949792","volume":"33","author":"E McElnea","year":"2014","unstructured":"McElnea E, A NM, Moran S, Kelly R, Fulcher T (2014) Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 33:424\u2013427. https:\/\/doi.org\/10.3109\/01676830.2014.949792","journal-title":"Orbit"},{"key":"7089_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaapos.2018.01.006","volume":"22","author":"ESY Park","year":"2018","unstructured":"Park ESY, Rabinowits G, Hamnvik OR, Dagi LR (2018) A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS 22:310\u2013312. https:\/\/doi.org\/10.1016\/j.jaapos.2018.01.006","journal-title":"J AAPOS"},{"key":"7089_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/IOP.0b013e3182895795","volume":"29","author":"MA Sohrab","year":"2013","unstructured":"Sohrab MA, Desai RU, Chambers CB, Lissner GS (2013) Re: \u201cDrug-induced Graves disease from CTLA-4 receptor suppression.\u201d Ophthalmic Plast Reconstr Surg 29:239\u2013240. https:\/\/doi.org\/10.1097\/IOP.0b013e3182895795","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, R\u00f8nningen KS, Guja C, Ionescu-T\u00eergovi\u015fte C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506\u2013511. https:\/\/doi.org\/10.1038\/nature01621","journal-title":"Nature"},{"key":"7089_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1677\/jme.0.0310021","volume":"31","author":"DA Chistiakov","year":"2003","unstructured":"Chistiakov DA, Turakulov RI (2003) CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 31:21\u201336. https:\/\/doi.org\/10.1677\/jme.0.0310021","journal-title":"J Mol Endocrinol"},{"key":"7089_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3109\/02713683.2014.993767","volume":"40","author":"H Wang","year":"2015","unstructured":"Wang H, Zhu LS, Cheng JW, Cai JP, Li Y, Ma XY, Wei RL (2015) Meta-analysis of association between the +\u200949A\/G polymorphism of cytotoxic T-lymphocyte antigen-4 and thyroid associated ophthalmopathy. Curr Eye Res 40:1195\u20131203. https:\/\/doi.org\/10.3109\/02713683.2014.993767","journal-title":"Curr Eye Res"},{"key":"7089_CR51","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/hmg\/8.7.1195","volume":"8","author":"B Vaidya","year":"1999","unstructured":"Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SH (1999) The cytotoxic T lymphocyte antigen-4 is a major Graves\u2019 disease locus. Hum Mol Genet 8:1195\u20131199. https:\/\/doi.org\/10.1093\/hmg\/8.7.1195","journal-title":"Hum Mol Genet"},{"key":"7089_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/09273948.2014.1001858","volume":"24","author":"E Papavasileiou","year":"2016","unstructured":"Papavasileiou E, Sashank P, K. FS, Lucia S, Lobo A-M (2016) Ipilimumab-induced ocular and orbital inflammation\u2014a case series and review of the literature. Ocul Immunol Inflamm 24:140\u2013146. https:\/\/doi.org\/10.3109\/09273948.2014.1001858","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"7089_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/iop.0000000000000033","volume":"30","author":"GE Borodic","year":"2014","unstructured":"Borodic GE, Hinkle D (2014) Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 30:83. https:\/\/doi.org\/10.1097\/iop.0000000000000033","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0002-9343(86)90181-6","volume":"81","author":"SL Rabinowe","year":"1986","unstructured":"Rabinowe SL, Larsen PR, Antman EM, George KL, Friedman PL, Jackson RA, Eisenbarth GS (1986) Amiodarone therapy and autoimmune thyroid disease. Increase in a new monoclonal antibody-defined T cell subset. Am J Med 81:53\u201357. https:\/\/doi.org\/10.1016\/0002-9343(86)90181-6","journal-title":"Am J Med"},{"key":"7089_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jecr.2025.100195","volume":"37","author":"TC Wilson","year":"2025","unstructured":"Wilson TC, Haenel LC (2025) Amiodarone-induced Grave\u2019s disease: development of the full Grave\u2019s spectrum following amiodarone therapy. J Clin Transl Endocrinol Case Rep 37:100195. https:\/\/doi.org\/10.1016\/j.jecr.2025.100195","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"7089_CR56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1600-0420.1997.tb00790.x","volume":"75","author":"K Sundelin","year":"1997","unstructured":"Sundelin K, Norrsell K (1997) Enlargement of extraocular muscles during treatment with amiodarone. Acta Ophthalmol Scand 75:333\u2013334. https:\/\/doi.org\/10.1111\/j.1600-0420.1997.tb00790.x","journal-title":"Acta Ophthalmol Scand"},{"key":"7089_CR57","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/iop.0000000000001012","volume":"34","author":"GR Slean","year":"2018","unstructured":"Slean GR, Silkiss RZ (2018) Lenalidomide-associated thyroid-related eyelid retraction. Ophthalmic Plast Reconstr Surg 34:e46\u2013e48. https:\/\/doi.org\/10.1097\/iop.0000000000001012","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7089_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/070674379303801002","volume":"38","author":"AP Byrne","year":"1993","unstructured":"Byrne AP, Delaney WJ (1993) Regression of thyrotoxic ophthalmopathy following lithium withdrawal. Can J Psychiatry 38:635\u2013637. https:\/\/doi.org\/10.1177\/070674379303801002","journal-title":"Can J Psychiatry"},{"key":"7089_CR59","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/archopht.1992.01080160030013","volume":"110","author":"AD Dick","year":"1992","unstructured":"Dick AD, Atta H, Forrester JV (1992) Lithium-induced orbitopathy. Arch Ophthalmol 110:452\u2013453. https:\/\/doi.org\/10.1001\/archopht.1992.01080160030013","journal-title":"Arch Ophthalmol"},{"key":"7089_CR60","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/nejm197307192890306","volume":"289","author":"RL Segal","year":"1973","unstructured":"Segal RL, Rosenblatt S, Eliasoph I (1973) Endocrine exophthalmos during lithium therapy of manic-depressive disease. N Engl J Med 289:136\u2013138. https:\/\/doi.org\/10.1056\/nejm197307192890306","journal-title":"N Engl J Med"},{"key":"7089_CR61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1192\/bjp.130.4.420","volume":"130","author":"MA Chaudhri","year":"1977","unstructured":"Chaudhri MA, Bebbington PE (1977) Lithium therapy and ophthalmic Graves\u2019 disease. Br J Psychiatry 130:420. https:\/\/doi.org\/10.1192\/bjp.130.4.420","journal-title":"Br J Psychiatry"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07089-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07089-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07089-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:37:18Z","timestamp":1773909438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07089-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7089"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07089-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors do not have any copyright and permissions to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Copyright and permissions"}}]}}